Related Experiment Video
Updated: Aug 19, 2026

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
Published on: August 11, 2015
Amitriptyline-perphenazine overdose producing delayed hypomania in manic-depressive illness
The authors describe a 26-year-old woman who became hypomanic after awakening from a semicomatose state induced by an overdose of amitriptyline-perphenazine (Triavil). She had been depressed and had a strong family history of manic-depressive illness. The case is reported to support previous evidence that dopamine is a mediator for mania.
The authors describe a 26-year-old woman who became hypomanic after awakening from a semicomatose state induced by an overdose of amitriptyline-perphenazine (Triavil). She had been depressed and had a strong family history of manic-depressive illness. The case is reported to support previous evidence that dopamine is a mediator for mania.
Related Concept Videos
Psychosis and Antipsychotic Drugs: Overview
Psychosis: Goals of Pharmacotherapy
Mania and Antimanic Drugs: Overview
Antidepressant Drugs: Tricyclics, SSRIs, and SNRIs
Antidepressant Drugs: MAOIs and Other Agents
Sedatives and Hypnotics Drugs: Miscellaneous Agents
Melatonin congeners like ramelteon (Rozerem) and tasimelteon (Hetlioz) selectively bind to melatonin receptors (MT1 and MT2) and thus mimic the actions of melatonin, a hormone that regulates sleep-wake cycles. Tasimelteon is primarily used for non-24-hour sleep-wake disorder, common in blind patients. They are also used to treat conditions like insomnia...

